Working… Menu

Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support (CD-NP/LVAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03091998
Recruitment Status : Withdrawn (No funding available)
First Posted : March 27, 2017
Last Update Posted : July 28, 2017
Information provided by (Responsible Party):
Tomoko Ichiki, M.D., Ph.D., Mayo Clinic

Brief Summary:

The worldwide use of left ventricular assist devices (LVAD), which is mechanical device to improve hemodynamic function, has improved the outcomes of severe heart failure (HF) patients leading to the continued annual increase in the number of LVAD implantations. However LVAD support still results in major complications such as renal failure or gastrointestinal bleeding. The investigators hypothesize that such major complications may be due to endothelial dysfunction induced by the lack of pulsatility, which may be improved by an innovative designer natriuretic peptide, CD-NP. They have demonstrated its favorable actions in animal models as well as humans, and tested its safety in LVAD patients. They hypothesize that CD-NP will have renal and endothelial protective actions through its receptor GC-A and GC-B. Thus, the investigators will test their hypothesis with a highly translational approach to examine CD-NP's role in endothelial and renal protection.

The aim is to determine safety and tolerability together with cGMP activating, neurohumoral modulating and renovascular protective properties of chronic subcutaneous delivery of CD-NP compared to placebo in stable LVAD patients for 3 days.

Condition or disease Intervention/treatment Phase
Heart Failure Left Ventricular Assist Device Natriuretic Peptide Drug: CD-NP Other: Placebo Phase 1

Detailed Description:
Stable patients with LVAD implantation (3 months s/p implantation) will undergo 3-day testing in the Mayo Clinic's Clinical Research and Trials Unit. They will undergo daily subcutaneous injection of CD-NP, or placebo, for 3 days with hemodynamic monitoring, ECHO, endothelial function assessment, and renal blood flow monitoring. Blood and urine samples will also be collected and assayed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Injection of CD-NP vs Placebo
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: The Research Pharmacists will manage the randomization of the study and release information at the conclusion, once all participants have been recruited and completed study measures.
Primary Purpose: Treatment
Official Title: A Phase I Trial to Determine Safety and Efficacy of Chronic Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
Estimated Study Start Date : September 30, 2017
Estimated Primary Completion Date : May 1, 2019
Estimated Study Completion Date : May 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Active Comparator: Study Drug (CD-NP)
Participants will receive a single subcutaneous injection of CD-NP (5 ug/kg) for 3 days running
Drug: CD-NP
Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days
Other Name: Cenderitide

Placebo Comparator: Placebo (saline)
Participants will receive a single subcutaneous injection (~1 mL) of normal saline for 3 days running
Other: Placebo
Participants will receive an ~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
Other Name: 0.9% normal saline

Primary Outcome Measures :
  1. Hypotension [ Time Frame: 2 weeks ]
    To assess safety and tolerability (without symptomatic hypotension or mean blood pressure <70 mmHg) of chronic continuous subcutaneous infusion administration of CD-NP.

Secondary Outcome Measures :
  1. Pharmacokinetic Outcome Characterization [ Time Frame: 2 weeks ]
    Area under the plasma concentration versus time curve (AUC) assessed by plasma CD-NP and cGMP

  2. Renal Function [ Time Frame: 2 weeks ]
    Estimated GFR from creatinine clearance and

  3. Endothelial function [ Time Frame: 2 weeks ]
    Measurement by Reactive Hyperemia-peripheral arterial tonometry (RHI)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and non-pregnant/post-menopausal/sterile females, ages 18-90, in end-stage HF with LVAD support who are stable in the healed stage at least 3 months from the LVAD implant (Destination therapy only) (the post-menopausal state is defined as the absence of menses for ≥ 1 year or serum follicle-stimulating hormone ≥ 20 IU/L; sterilization in the female is defined as bilateral tubal occlusion for ≥ 6 months, bilateral oophorectomy, or complete hysterectomy)
  • Be willing to provide informed consent.
  • All cardiac medications must be at stable doses 4 weeks prior to enrollment.

Exclusion Criteria:

  • Known allergy or other adverse reactions to exogenous natriuretic peptides (CD-NP or its components, nesiritide, other natriuretic peptides, or related compounds).
  • Women who are pregnant, or breast-feeding.
  • Having received nesiritide within 7 days prior to entry into the study.
  • Having received any investigational drug or device within 30 days prior to entry into the study.
  • Clinically unstable patients (e.g. mean blood pressure < 70 mmHg, ongoing requirement for vasopressors, or mechanical ventilation).
  • Recent hospitalization for decompensated HF or recent defibrillation for cardiac resuscitation within 30 days prior to randomization.
  • Patients with guarded prognosis who are unlikely to derive meaningful benefit from CD-NP.
  • Presence of cardiac lesions or comorbidities that may contraindicate the use of natriuretic peptides, such as clinically significant cardiac valvular stenosis, hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or uncorrected congenital heart disease that contraindicates the use of vasodilators.
  • Symptomatic carotid artery disease, known critical carotid stenosis, or stroke within the past 3 months
  • Requirement of pressors for maintenance of blood pressure.
  • Intra-aortic blood pump use.
  • Severe aortic or mitral stenosis or significant LV outflow tract obstruction.
  • Clinically significant renal artery stenosis > 50%
  • Baseline hemoglobin < 9.0 g/dl.
  • Serum sodium < 130 mEq/L, potassium < 3.6 mEq/L, or magnesium < 1.5 mEq/L.
  • Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at least 5 times the upper limit of normal or bilirubin at least 5 times the upper limit of normal
  • Creatinine clearance (CrCl) < 30 ml.min-1.1.73m-2, as calculated by Cockcroft-Gault formula(67) and adjusted for body surface area within 3 months or requirement for dialysis.
  • Written history of alcohol or drug abuse within the past 6 months.
  • Inability to communicate effectively with study personnel.
  • BMI >40

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03091998

Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Tomoko Ichiki, M.D.Ph.D. Mayo Clinic

Layout table for additonal information
Responsible Party: Tomoko Ichiki, M.D., Ph.D., Associate Professor of Medicine, Mayo Clinic Identifier: NCT03091998     History of Changes
Other Study ID Numbers: IRB # 16-004850
First Posted: March 27, 2017    Key Record Dates
Last Update Posted: July 28, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases